应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ADC 艾格里房产
休市中 05-17 16:00:00 EDT
60.53
+0.17
+0.28%
盘后
60.53
+0.00
0.00%
19:45 EDT
最高
60.62
最低
60.18
成交量
53.76万
今开
60.38
昨收
60.36
日振幅
0.73%
总市值
60.77亿
流通市值
59.76亿
总股本
1.00亿
成交额
3,249万
换手率
0.54%
流通股本
9,873万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
基石药业-B现涨逾11% ROR1 ADC最新研究数据即将亮相ASCO
新浪港股 · 05-16 11:54
基石药业-B现涨逾11% ROR1 ADC最新研究数据即将亮相ASCO
港股异动 | 基石药业-B(02616)涨超12% ROR1 ADC最新研究数据即将亮相ASCO 全球空间有望超百亿美元
智通财经 · 05-16 11:39
港股异动 | 基石药业-B(02616)涨超12% ROR1 ADC最新研究数据即将亮相ASCO 全球空间有望超百亿美元
Nuvation Bio Inc.盘中异动 股价大涨5.59%
自选股智能写手 · 05-09
Nuvation Bio Inc.盘中异动 股价大涨5.59%
百利天恒(688506.SH)：注射用BL-B16D1(双抗ADC)项目治疗晚期实体瘤获批I期临床试验
智通财经 · 05-09
百利天恒(688506.SH)：注射用BL-B16D1(双抗ADC)项目治疗晚期实体瘤获批I期临床试验
FibroGen to Participate in Upcoming Investor Conferences
GlobeNewswire · 05-07
FibroGen to Participate in Upcoming Investor Conferences
信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期胃/胃食管交界处腺癌患者
美通社 · 05-07
信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期胃/胃食管交界处腺癌患者
ADC Therapeutics(ADCT.US)：2024年Q1财报实现营收1805.3万美元，前
智通财经 · 05-06
ADC Therapeutics(ADCT.US)：2024年Q1财报实现营收1805.3万美元，前
辉瑞ADC药物TIVDAK获美国FDA完全批准，用于治疗复发性或转移性宫颈癌
新浪财经 · 05-06
辉瑞ADC药物TIVDAK获美国FDA完全批准，用于治疗复发性或转移性宫颈癌
辉瑞(PFE)用于治疗复发性或转移性宫颈癌的ADC药物TIVDAK获美FDA完全批准
金吾财讯 · 05-06
辉瑞(PFE)用于治疗复发性或转移性宫颈癌的ADC药物TIVDAK获美FDA完全批准
基石药业-B(02616)将在2024年美国临床肿瘤学会年会上公布CS5001(ROR1 ADC)I期研究数据
智通财经 · 05-06
基石药业-B(02616)将在2024年美国临床肿瘤学会年会上公布CS5001(ROR1 ADC)I期研究数据
Nuvation Bio Inc.盘中异动 早盘大幅拉升5.02%
自选股智能写手 · 05-01
Nuvation Bio Inc.盘中异动 早盘大幅拉升5.02%
Nuvation Bio Inc.盘中异动 早盘股价大涨6.53%报2.86美元
自选股智能写手 · 04-29
Nuvation Bio Inc.盘中异动 早盘股价大涨6.53%报2.86美元
在增长平台和新药的推动下，益普生2024年第一季度实现销售额强劲增长并确认2024年全年指引
美通社 · 04-29
在增长平台和新药的推动下，益普生2024年第一季度实现销售额强劲增长并确认2024年全年指引
FibroGen to Report First Quarter 2024 Financial Results
GlobeNewswire · 04-29
FibroGen to Report First Quarter 2024 Financial Results
Nuvation Bio Inc.盘中异动 快速拉升5.34%报2.76美元
自选股智能写手 · 04-27
Nuvation Bio Inc.盘中异动 快速拉升5.34%报2.76美元
ADC赛道投资分水岭显现，“错锋竞争+造血研发”成新风向标？
智通财经 · 04-26
ADC赛道投资分水岭显现，“错锋竞争+造血研发”成新风向标？
港股异动 | 科伦博泰生物-B(06990)涨超6% 背靠默沙东23年营收大涨 SKB264有望成泛癌种显著获益的ADC大单品
智通财经 · 04-25
港股异动 | 科伦博泰生物-B(06990)涨超6% 背靠默沙东23年营收大涨 SKB264有望成泛癌种显著获益的ADC大单品
信达生物将在美国临床肿瘤学会（ASCO）2024年大会公布多项临床数据
美通社 · 04-25
信达生物将在美国临床肿瘤学会（ASCO）2024年大会公布多项临床数据
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese
StreetInsider · 04-25
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese
Agree Realty Corp 公布截至 3 月的季度业绩 - 盈利摘要
Reuters · 04-24
Agree Realty Corp 公布截至 3 月的季度业绩 - 盈利摘要
加载更多
公司概况
公司名称：
艾格里房产
所属市场：
NYSE
上市日期：
--
主营业务：
Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。
发行价格：
--
{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":60.53,"timestamp":1715976000000,"preClose":60.36,"halted":0,"volume":537554,"hourTrading":{"tag":"盘后","latestPrice":60.53,"preClose":60.53,"latestTime":"19:45 EDT","volume":21666,"amount":1311441.69,"timestamp":1715989539096},"delay":0,"floatShares":98732099,"shares":100394948,"eps":1.691249,"marketStatus":"休市中","marketStatusCode":7,"change":0.17,"latestTime":"05-17 16:00:00 EDT","open":60.38,"high":60.62,"low":60.18,"amount":32491657.562742,"amplitude":0.00729,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.691249,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"listingDate":766296000000,"adjPreClose":60.36,"adrRate":0,"dividendRate":0.048571,"preHourTrading":{"tag":"盘前","latestPrice":60.36,"preClose":60.36,"latestTime":"09:23 EDT","volume":28074,"amount":1694544.39408,"timestamp":1715952212169},"postHourTrading":{"tag":"盘后","latestPrice":60.53,"preClose":60.53,"latestTime":"19:45 EDT","volume":21666,"amount":1311441.69,"timestamp":1715989539096},"volumeRatio":0.8335651573131787},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2435610424","title":"基石药业-B现涨逾11% ROR1 ADC最新研究数据即将亮相ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2435610424","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2435610424?lang=zh_cn&edition=full","pubTime":"2024-05-16 11:54","pubTimestamp":1715831640,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 基石药业-B（02616）早盘上涨10.91%，现报1.22港元，成交额310.071万港元。\n 2024年美国临床肿瘤学会（ASCO）年会将于美国东部时间5月31日至6月4日在芝加哥以线上和线下相结合的形式展开，该会议是全球肿瘤学领域最重要的会议之一。在国盛证券盘点的2024 ASCO ADC重点临床中，包括了基石药业CS5001治疗晚期实体瘤和淋巴瘤患者的1a/1b期、全球多中心、首次人体研究。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-16/doc-inavkyri9822699.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-16/doc-inavkyri9822699.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435061728","title":"港股异动 | 基石药业-B(02616)涨超12% ROR1 ADC最新研究数据即将亮相ASCO 全球空间有望超百亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435061728","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435061728?lang=zh_cn&edition=full","pubTime":"2024-05-16 11:39","pubTimestamp":1715830782,"startTime":"0","endTime":"0","summary":"在国盛证券盘点的2024 ASCO ADC重点临床中，包括了基石药业CS5001治疗晚期实体瘤和淋巴瘤患者的1a/1b期、全球多中心、首次人体研究。西南证券此前指出，CS5001 是一款ROR1 ADC，ROR1 ADC全球仅三款处于临床阶段，前两款分别以27.5 亿和14.3 亿美元的高价被MSD和勃林格殷格翰收购。究其原因，ROR1为肿瘤胚胎蛋白，高表达于多种实体瘤和血液瘤，如非小细胞肺癌、白血病、淋巴瘤等，全球患者人群达300万人，一旦成药，空间有望达数百亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121866.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434018127","title":"Nuvation Bio Inc.盘中异动 股价大涨5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434018127","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434018127?lang=zh_cn&edition=full","pubTime":"2024-05-09 21:30","pubTimestamp":1715261425,"startTime":"0","endTime":"0","summary":"北京时间2024年05月09日21时30分，Nuvation Bio Inc.股票出现波动，股价大幅拉升5.59%。截至发稿，该股报3.40美元/股，成交量3.4888万股，换手率0.01%，振幅1.55%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.56%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240509213026861ec175&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240509213026861ec175&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434916990","title":"百利天恒(688506.SH)：注射用BL-B16D1(双抗ADC)项目治疗晚期实体瘤获批I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2434916990","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434916990?lang=zh_cn&edition=full","pubTime":"2024-05-09 20:11","pubTimestamp":1715256671,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司自主研发的创新生物药BL-B16D1(双抗ADC)，于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。BL-B16D1是公司自主研发的偶联了新一代毒素的双抗ADC药物，其适应症为晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119486.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433279419","title":"FibroGen to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2433279419","media":"GlobeNewswire","top":-1,"share":"https://www.laohu8.com/m/news/2433279419?lang=zh_cn&edition=full","pubTime":"2024-05-07 11:00","pubTimestamp":1715050800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc.(NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America Hea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/07/2876528/33525/en/FibroGen-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433250837","title":"信达生物IBI343 (CLDN 18.2 ADC) 获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期胃/胃食管交界处腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2433250837","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2433250837?lang=zh_cn&edition=full","pubTime":"2024-05-07 08:07","pubTimestamp":1715040420,"startTime":"0","endTime":"0","summary":"据本次BTD申请资料，IBI343单药在晚期胃/胃食管交界处腺癌患者中显示了令人鼓舞的疗效和良好的耐受性。目前，氟嘧啶和铂类联合治疗的化疗及免疫检查点抑制剂治疗是晚期转移性胃癌患者的标准治疗。CLDN18.2 在胃癌患者中表达率达 80%。IBI343与表达CLDN18.2的肿瘤细胞结合后，发生CLDN18.2依赖性内化，随后可裂解的连接子降解，从而释放的药物引起DNA损伤，导致肿瘤细胞凋亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4406031_ZH06031_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433235424","title":"ADC Therapeutics(ADCT.US)：2024年Q1财报实现营收1805.3万美元，前","url":"https://stock-news.laohu8.com/highlight/detail?id=2433235424","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433235424?lang=zh_cn&edition=full","pubTime":"2024-05-06 18:37","pubTimestamp":1714991838,"startTime":"0","endTime":"0","summary":"ADC Therapeutics(ADCT.US)：2024年Q1财报实现营收1805.3万美元，前值为1899.2万美元，预期值为1821万美元；每股收益为-0.38美元，前值为-0.53美元，预期值为-0.56美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061847258ae0fc6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061847258ae0fc6f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433445521","title":"辉瑞ADC药物TIVDAK获美国FDA完全批准，用于治疗复发性或转移性宫颈癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2433445521","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2433445521?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:46","pubTimestamp":1714985188,"startTime":"0","endTime":"0","summary":"5月6日，再鼎医药官微宣布，合作伙伴辉瑞公司和Genmab联合宣布美国食品药品监督管理局（FDA）已经批准了TIVDAK®（tisotumab vedotin-tftv）的补充生物制剂许可申请（sBLA），完全批准其用于治疗化疗期间或化疗后疾病发生进展的复发性或转移性宫颈癌患者。（界面新闻）\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-05-06/doc-inauhrwv3095368.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433431294","title":"辉瑞(PFE)用于治疗复发性或转移性宫颈癌的ADC药物TIVDAK获美FDA完全批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2433431294","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2433431294?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:24","pubTimestamp":1714983859,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(09688、ZLAB)宣布，合作伙伴辉瑞公司(PFE)和Genmab联合宣布美国食品药品监督管理局（FDA）已经批准了TIVDAK®（tisotumab vedotin-tftv）的补充生物制剂许可申请（sBLA），完全批准其用于治疗化疗期间或化疗后疾病发生进展的复发性或转移性宫颈癌患者。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NzhiZDQ4N2Q4MzQwNjg3YThiMjQyY2JmMzE4MDg0MDY1NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzhiZDQ4N2Q4MzQwNjg3YThiMjQyY2JmMzE4MDg0MDY1NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"275553","is_publish_highlight":false,"gpt_icon":0},{"id":"2433499955","title":"基石药业-B(02616)将在2024年美国临床肿瘤学会年会上公布CS5001(ROR1 ADC)I期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2433499955","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433499955?lang=zh_cn&edition=full","pubTime":"2024-05-06 12:06","pubTimestamp":1714968375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司研发管线2.0的重磅产品CS5001最新研究数据将在2024年美国临床肿瘤学会年会上以壁报形式展示。本届ASCO年会将于2024年5月31日至6月4日在美国芝加哥举行。壁报展示时间： 2024年6月1日，上午9:00-12:00。据悉，CS5001是一款临床阶段以受体酪氨酸激酶样孤儿受体1为靶点的抗体偶联药物。根据协定条款，基石药业获得CS5001在韩国以外的全球其他地区的独家开发和商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117408.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432680570","title":"Nuvation Bio Inc.盘中异动 早盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432680570","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432680570?lang=zh_cn&edition=full","pubTime":"2024-05-01 21:38","pubTimestamp":1714570704,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日21时38分，Nuvation Bio Inc.股票出现异动，股价快速上涨5.02%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Cytomx Therapeutics, Inc.、Palisade Bio, Inc.、Tg Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Cytomx Therapeutics, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为445.14%、39.17%、15.94%，振幅较大的相关个股有Promis Neurosciences Inc.、Carmell Corporation、Cytomx Therapeutics, Inc.，振幅分别为23.46%、21.50%、19.63%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012138257a57db6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012138257a57db6b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431863740","title":"Nuvation Bio Inc.盘中异动 早盘股价大涨6.53%报2.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431863740","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431863740?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:32","pubTimestamp":1714397545,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日21时32分，Nuvation Bio Inc.股票出现波动，股价急速上涨6.53%。截至发稿，该股报2.86美元/股，成交量2.5567万股，换手率0.01%，振幅0.97%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.56%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292132268b624e89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292132268b624e89&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431868972","title":"在增长平台和新药的推动下，益普生2024年第一季度实现销售额强劲增长并确认2024年全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2431868972","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431868972?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:06","pubTimestamp":1714395960,"startTime":"0","endTime":"0","summary":"巴黎2024年4月29日 /美通社/ -- 全球特药领域生物制药公司益普生今日公布了2024年第一季度的销售业绩。益普生和Skyhawk Therapeutics于2024年4月宣布签署全球独家合作协议，共同发现和开发调节罕见神经系统疾病RNA的新型小分子药物。该协议包括一项选择权，根据该选择权，益普生将获得在全球范围内开发成功候选药物的独家许可。本报告的业绩涵盖2024年3月31日之前的3个月期间，而进行数据对比的对象为2023年3月31日之前的3个月期间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4399713_ZH99713_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431530834","title":"FibroGen to Report First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2431530834","media":"GlobeNewswire","top":-1,"share":"https://www.laohu8.com/m/news/2431530834?lang=zh_cn&edition=full","pubTime":"2024-04-29 11:00","pubTimestamp":1714359600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/29/2871074/33525/en/FibroGen-to-Report-First-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430200527","title":"Nuvation Bio Inc.盘中异动 快速拉升5.34%报2.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430200527","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430200527?lang=zh_cn&edition=full","pubTime":"2024-04-27 00:03","pubTimestamp":1714147388,"startTime":"0","endTime":"0","summary":"北京时间2024年04月27日00时03分，Nuvation Bio Inc.股票出现异动，股价急速拉升5.34%。截至发稿，该股报2.76美元/股，成交量25.1378万股，换手率0.10%，振幅4.81%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240427000308861e9969&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240427000308861e9969&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430241913","title":"ADC赛道投资分水岭显现，“错锋竞争+造血研发”成新风向标？","url":"https://stock-news.laohu8.com/highlight/detail?id=2430241913","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430241913?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:18","pubTimestamp":1714119495,"startTime":"0","endTime":"0","summary":"今年4月3日，丹麦药企Genmab宣布将以18亿美元全现金交易形式收购一家中国本土的ADC药物研发Biotech普方生物，从而获得其自主研发的ADC技术资产。此前国金证券公布的一份研报也显示，国内ADC在研药物有超过60个是靶向HER2，位居首位。但在强调差异化的ADC赛道，聚集成熟靶点并非一件好事，随着市场竞争趋于白热化，研发企业能否从有限的适应症市场分得一杯羹成为一个未知数，也影响市场对公司后续价值的判断。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111461.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430417534","title":"港股异动 | 科伦博泰生物-B(06990)涨超6% 背靠默沙东23年营收大涨 SKB264有望成泛癌种显著获益的ADC大单品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430417534","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430417534?lang=zh_cn&edition=full","pubTime":"2024-04-25 10:11","pubTimestamp":1714011099,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B涨超6%，截止发稿涨6.04%，报163.3港元，成交额2002万港元。业绩方面，3月25日公司发布了上市以来的首份年报。据悉目前科伦博泰与默沙东共有7款处于合作进程中的产品。基于上述合作，2023年，科伦博泰共从默沙东处获取了14.21亿元的首付款及里程碑款项，占公司年内营收的92.27%。此外，科伦博泰SKB264目前正在全球范围内开展针对多个瘤种的单药/联用的Ⅱ期和Ⅲ期临床试验，有望成为泛癌种显著获益的ADC大单品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109521.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430589417","title":"信达生物将在美国临床肿瘤学会（ASCO）2024年大会公布多项临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2430589417","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2430589417?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:50","pubTimestamp":1714009800,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年4月25日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在 2024 年美国临床肿瘤学会年会上公布约20项最新临床研究数据，包括公司旗下一系列单抗、双抗及抗体偶联药物在研管线，及达伯舒、耐立克、他雷替尼等创新肿瘤药物。本届 ASCO 年会将于当地时间2024年5月31日-6月4日在美国芝加哥举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4396236_ZH96236_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430989684","title":"FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese","url":"https://stock-news.laohu8.com/highlight/detail?id=2430989684","media":"StreetInsider","top":-1,"share":"https://www.laohu8.com/m/news/2430989684?lang=zh_cn&edition=full","pubTime":"2024-04-25 04:02","pubTimestamp":1713988920,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23110673","is_publish_highlight":false,"gpt_icon":0},{"id":"2429140500","title":"Agree Realty Corp 公布截至 3 月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2429140500","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429140500?lang=zh_cn&edition=full","pubTime":"2024-04-24 05:01","pubTimestamp":1713906119,"startTime":"0","endTime":"0","summary":" * Agree Realty Corp 公布的截至 3 月份的季度调整后每股收益为 47 美分，高于去年同期的每股收益 44 美分。五位分析师对该季度的平均预期为每股收益 46 美分。* Agree Realty Corp 公布的本季度每股收益为 43 美分。* 公司报告的季度净收入为 4300 万美元。* 本季度，Agree Realty Corp 的股价下跌了 0.4%，今年迄今为止下跌了 9.6%。4月23日 - 预测变化 * 过去三个月，分析师的平均盈利预期下降了约 0.3%。* 华尔街对 Agree Realty Corp 的 12 个月目标价中位数为 65.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":0.097},{"period":"3month","weight":0.0614},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0837},{"period":"ytd","weight":-0.0384}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":-0.004913},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.016968},{"month":6,"riseRate":0.666667,"avgChangeRate":0.011142},{"month":7,"riseRate":0.666667,"avgChangeRate":0.021205},{"month":8,"riseRate":0.433333,"avgChangeRate":-0.000088},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.007022},{"month":10,"riseRate":0.566667,"avgChangeRate":-0.000808},{"month":11,"riseRate":0.633333,"avgChangeRate":0.001669},{"month":12,"riseRate":0.5,"avgChangeRate":0.014772}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}